- Home
- HFBL vs SNTI Comparison
HFBL vs SNTI Comparison
Compare HFBL & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HFBL
- SNTI
- Stock Information
- Founded
- HFBL 1924
- SNTI 2016
- Country
- HFBL United States
- SNTI United States
- Employees
- HFBL N/A
- SNTI N/A
- Industry
- HFBL Savings Institutions
- SNTI Biotechnology: Pharmaceutical Preparations
- Sector
- HFBL Finance
- SNTI Health Care
- Exchange
- HFBL Nasdaq
- SNTI Nasdaq
- Market Cap
- HFBL 41.3M
- SNTI 39.6M
- IPO Year
- HFBL N/A
- SNTI N/A
- Fundamental
- Price
- HFBL $13.40
- SNTI $1.54
- Analyst Decision
- HFBL
- SNTI Strong Buy
- Analyst Count
- HFBL 0
- SNTI 2
- Target Price
- HFBL N/A
- SNTI $8.50
- AVG Volume (30 Days)
- HFBL 1.4K
- SNTI 107.8K
- Earning Date
- HFBL 10-28-2025
- SNTI 08-07-2025
- Dividend Yield
- HFBL 3.99%
- SNTI N/A
- EPS Growth
- HFBL 6.78
- SNTI N/A
- EPS
- HFBL 1.26
- SNTI N/A
- Revenue
- HFBL $20,802,000.00
- SNTI N/A
- Revenue This Year
- HFBL N/A
- SNTI N/A
- Revenue Next Year
- HFBL N/A
- SNTI $150.00
- P/E Ratio
- HFBL $10.33
- SNTI N/A
- Revenue Growth
- HFBL 1.50
- SNTI N/A
- 52 Week Low
- HFBL $11.75
- SNTI $1.46
- 52 Week High
- HFBL $14.25
- SNTI $16.94
- Technical
- Relative Strength Index (RSI)
- HFBL 42.77
- SNTI 40.73
- Support Level
- HFBL $13.00
- SNTI $1.52
- Resistance Level
- HFBL $13.44
- SNTI $1.61
- Average True Range (ATR)
- HFBL 0.08
- SNTI 0.09
- MACD
- HFBL -0.01
- SNTI 0.03
- Stochastic Oscillator
- HFBL 4.55
- SNTI 67.50
About HFBL Home Federal Bancorp Inc. of Louisiana
Home Federal Bancorp Inc of louisiana operates as a bank holding company. It is a federally chartered stock savings bank, which provides financial services to individuals, corporate entities, and other organizations. Its core activities consist of attracting deposits from the general public and using those funds to originate loans to the residential, commercial and multi-family segments. The company also invests securities held-to-maturity and securities available for sale.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.